Numerous attempts to make CAR-Ts work in solid tumors have failed in recent years, but AstraZeneca has caught attention this week with promising Phase I data for its candidate, C-CAR031 (AZD7003), presented at the American Society of Oncology meeting in Chicago.
ASCO: AstraZeneca Achieves Eye-Catching Solid Tumor Results With 'Armored' CAR-T
Solid tumor CAR-T may succeed AZD7003 where many others have failed as the firm builds its cell therapy pipeline.

More from Clinical Trials
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
A decision from the FDA is due by 28 September.
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
More from R&D
A decision from the FDA is due by 28 September.
A new “quasi-experimental” study using UK National Health Service data might confirm that GSK’s shingles vaccine helps cut dementia cases.
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process